EP3621600A4 - Procédés pour le traitement d'un glioblastome récurrent (rgbm) - Google Patents

Procédés pour le traitement d'un glioblastome récurrent (rgbm) Download PDF

Info

Publication number
EP3621600A4
EP3621600A4 EP18797766.5A EP18797766A EP3621600A4 EP 3621600 A4 EP3621600 A4 EP 3621600A4 EP 18797766 A EP18797766 A EP 18797766A EP 3621600 A4 EP3621600 A4 EP 3621600A4
Authority
EP
European Patent Office
Prior art keywords
rgbm
glioblastoma
recurring
processes
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP18797766.5A
Other languages
German (de)
English (en)
Other versions
EP3621600A1 (fr
Inventor
Stanislaw R. Burzynski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP3621600A1 publication Critical patent/EP3621600A1/fr
Publication of EP3621600A4 publication Critical patent/EP3621600A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Oncology (AREA)
EP18797766.5A 2017-05-08 2018-05-07 Procédés pour le traitement d'un glioblastome récurrent (rgbm) Withdrawn EP3621600A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/589,887 US10624869B2 (en) 2017-05-08 2017-05-08 Methods for the treatment of recurrent glioblastoma (RGBM)
PCT/US2018/031456 WO2018208697A1 (fr) 2017-05-08 2018-05-07 Procédés pour le traitement d'un glioblastome récurrent (rgbm)

Publications (2)

Publication Number Publication Date
EP3621600A1 EP3621600A1 (fr) 2020-03-18
EP3621600A4 true EP3621600A4 (fr) 2021-03-24

Family

ID=64013505

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18797766.5A Withdrawn EP3621600A4 (fr) 2017-05-08 2018-05-07 Procédés pour le traitement d'un glioblastome récurrent (rgbm)

Country Status (11)

Country Link
US (4) US10624869B2 (fr)
EP (1) EP3621600A4 (fr)
JP (1) JP7169297B2 (fr)
CN (1) CN110996927A (fr)
AU (2) AU2018266375B2 (fr)
CA (1) CA3062741A1 (fr)
EA (1) EA201992658A1 (fr)
IL (1) IL270543B2 (fr)
MX (1) MX2019013345A (fr)
MY (1) MY194576A (fr)
WO (1) WO2018208697A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10624869B2 (en) 2017-05-08 2020-04-21 Stanislaw R. Burzynski Methods for the treatment of recurrent glioblastoma (RGBM)
EA202090024A1 (ru) * 2017-06-12 2020-04-10 Станислав Р. Бурзинский Способы лечения лептоменингеального заболевания
US11344521B2 (en) 2017-06-12 2022-05-31 Burzynski Research Institute, Inc. Methods for the treatment of leptomeningeal disease
US20230190694A1 (en) * 2021-11-03 2023-06-22 Stanislaw R. Burzynski Compositions for and methods of precision cancer treatment
JP2025516658A (ja) * 2022-05-11 2025-05-30 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 既製の免疫療法のためのｎｋ細胞製品の凍結保存
EP4568663A1 (fr) * 2022-08-08 2025-06-18 Stanislaw R. Burzynski Compositions et procédés de précision de traitement du cancer
WO2024263804A2 (fr) * 2023-06-20 2024-12-26 Burzynski Stanislaw R Compositions comprenant des antinéoplastons et méthodes de traitement du cancer du rein
WO2024263798A1 (fr) * 2023-06-20 2024-12-26 Burzynski Stanislaw R Compositions comprenant des antinéoplastons et méthodes de traitement du cancer de la prostate
WO2024263801A2 (fr) * 2023-06-20 2024-12-26 Burzynski Stanislaw R Compositions comprenant des antinéoplastons et méthodes de traitement du cancer de l'ovaire
EP4731199A2 (fr) * 2023-06-21 2026-04-29 Stanislaw R. Burzynski Compositions comprenant des antinéoplastons et méthodes de traitement du cancer colorectal
WO2024263972A2 (fr) * 2023-06-21 2024-12-26 Burzynski Stanislaw R Compositions comprenant des antinéoplastons et méthodes de traitement de cancers peu communs

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997042939A1 (fr) * 1996-05-14 1997-11-20 Burzynski Research Inst Traitements liposomaux par antineoplastons presentant une activite antineoplasique nettement amelioree

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258849B1 (en) 1998-07-23 2001-07-10 Stanislaw R. Burzynski Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
US20020103141A1 (en) 1998-12-23 2002-08-01 Mckearn John P. Antiangiogenic combination therapy for the treatment of cancer
CA2563797A1 (fr) 2004-04-22 2005-11-10 The University Of Utah Trousses et reactifs utilises pour diagnostiquer et pronostiquer des troubles genomiques
TW201536278A (zh) 2013-05-31 2015-10-01 Del Mar Pharmaceuticals 雙脫水半乳糖醇及其類似物與衍生物用於治療復發性惡性神經膠瘤或進行性繼發腦瘤之用途
ES2622983T3 (es) 2015-02-11 2017-07-10 Deutsches Krebsforschungszentrum Terapia contra el cáncer con un parvovirus combinado con bevacizumab
US10624869B2 (en) 2017-05-08 2020-04-21 Stanislaw R. Burzynski Methods for the treatment of recurrent glioblastoma (RGBM)
EA202090024A1 (ru) 2017-06-12 2020-04-10 Станислав Р. Бурзинский Способы лечения лептоменингеального заболевания
US11334521B2 (en) 2018-12-21 2022-05-17 EMC IP Holding Company LLC System and method that determines a size of metadata-based system snapshots

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997042939A1 (fr) * 1996-05-14 1997-11-20 Burzynski Research Inst Traitements liposomaux par antineoplastons presentant une activite antineoplasique nettement amelioree

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BURZYNSKI S R ET AL: "INITIAL CLINICAL STUDY WITH ANTINEOPLASTON A2 INJECTIONS IN CANCER PATIENTS WITH FIVE YEARS' FOLLOW-UP", DRUGS UNDER EXPERIMENTAL AND CLINICAL RESEARCH, BIOSCIENCE EDIPRINT INC, CH, vol. XIII, no. SUPPL. 01, 1 January 1987 (1987-01-01), pages 1 - 12, XP008000446, ISSN: 0378-6501 *
BURZYNSKI STANISLAW R. ET AL: "Recurrent Glioblastoma Multiforme-A Strategy for Long-Term Survival", JOURNAL OF CANCER THERAPY, vol. 05, no. 10, 1 January 2014 (2014-01-01), pages 957 - 976, XP093181465, ISSN: 2151-1934, Retrieved from the Internet <URL:https://www.scirp.org/pdf/JCT_2014091014473853.pdf> DOI: 10.4236/jct.2014.510101 *
MA DANIEL J. ET AL: "A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K", NEURO-ONCOLOGY, vol. 17, no. 9, 1 September 2015 (2015-09-01), US, pages 1261 - 1269, XP055776395, ISSN: 1522-8517, DOI: 10.1093/neuonc/nou328 *
See also references of WO2018208697A1 *
STANISLAW R. BURZYNSKI ET AL: "Preliminary Findings on the Use of Targeted Therapy with Pazopanib and Other Agents in Combination with Sodium Phenylbutyrate in the Treatment of Glioblastoma Multiforme", JOURNAL OF CANCER THERAPY, vol. 05, no. 14, 1 January 2014 (2014-01-01), pages 1423 - 1437, XP055546701, ISSN: 2151-1934, DOI: 10.4236/jct.2014.514144 *
VALERIOTE F ET AL: "SYNERGISTIC INTERACTION OF ANTICANCER AGENTS: A CELLULAR PERSPECTIVE", CANCER CHEMOTHERAPY REPORTS, XX, XX, vol. 59, no. 5, 1 September 1975 (1975-09-01), pages 895 - 900, XP009019750 *

Also Published As

Publication number Publication date
US12186290B2 (en) 2025-01-07
JP2020524129A (ja) 2020-08-13
US20200345674A1 (en) 2020-11-05
US20220151968A1 (en) 2022-05-19
WO2018208697A1 (fr) 2018-11-15
AU2018266375A1 (en) 2020-01-02
CA3062741A1 (fr) 2018-11-15
IL270543B2 (en) 2025-04-01
EP3621600A1 (fr) 2020-03-18
AU2024200203A1 (en) 2024-02-01
US20180318421A1 (en) 2018-11-08
AU2024200203B2 (en) 2025-08-14
US10624869B2 (en) 2020-04-21
JP7169297B2 (ja) 2022-11-10
US20250213515A1 (en) 2025-07-03
AU2018266375B2 (en) 2023-10-19
MX2019013345A (es) 2022-10-28
MY194576A (en) 2022-12-02
EA201992658A1 (ru) 2020-04-15
US11234951B2 (en) 2022-02-01
IL270543B1 (en) 2024-12-01
CN110996927A (zh) 2020-04-10
IL270543A (en) 2020-01-30

Similar Documents

Publication Publication Date Title
MA46836A (fr) Agents, utilisations et procédés pour le traitement d&#39;une synucléinopathie
EP3641829A4 (fr) Promédicament d&#39;interféron pour le traitement du cancer
MA47719A (fr) Esketamine pour le traitement de la dépression
MA42439A (fr) Agents, utilisations et procédés pour le traitement d&#39;une synucléinopathie
MA49144A (fr) Polythérapies pour le traitement du cancer
MA71705A (fr) Substances et procédés pour le traitement d&#39;hémoglobinopathies
EP3496666A4 (fr) Dispositifs et procédés pour le traitement d&#39;une insuffisance valvulaire
MA45539A (fr) Dihydropyranopyrimidines pour le traitement d&#39;infections virales
MA50849A (fr) Substances et procédés pour le traitement d&#39;hémoglobinopathies
EP3324973A4 (fr) Systèmes et procédés pour le traitement de l&#39; il avec un photosensibilisateur
EP4139348A4 (fr) Procédés et compositions pour le traitement d&#39;une inflammation associée à un virus
EP3481387A4 (fr) Methodes et compositions pour le traitement de troubles épileptiques
EP3494142A4 (fr) Anticorps anti-siglec-7 pour le traitement du cancer
MA45481A (fr) Utilisation d&#39;exosomes pour le traitement de maladies
EP3397963A4 (fr) Inhibition de mapk p38 pour le traitement du cancer
MA50409A (fr) Polythérapies pour le traitement du cancer
MA48637A (fr) Polythérapies pour le traitement du cancer
MA43170A (fr) Association d&#39;un inhibiteur de bcl-2 et d&#39;un inhibiteur de mek pour le traitement du cancer
EP3645040A4 (fr) Utilisation d&#39;anticorps anti-fam19a5 pour le traitement de cancers
EP3383282A4 (fr) Dispositifs et procédés pour le traitement de l&#39;insuffisance rénale aiguë
EP3319534A4 (fr) Systèmes et procédés pour le traitement et la prévention d&#39;un dysfonctionnement pelvien féminin
EP3541417A4 (fr) Immunothérapies d&#39;association pour le traitement du cancer
MA43825A (fr) Schémas posologiques pour le traitement d&#39;infections fongiques
EP3423048A4 (fr) Polythérapie pour le traitement du cancer de l&#39;ovaire
EP3541379A4 (fr) Compositions pour le traitement de l&#39;hypertension

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20191206

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40016080

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20210224

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20210218BHEP

Ipc: A61K 31/00 20060101AFI20210218BHEP

Ipc: A61K 31/19 20060101ALI20210218BHEP

Ipc: A61K 31/20 20060101ALI20210218BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240708

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20260116